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Abstract
Introduction: Necrotising fasciitis is a severe infection characterised by the fulminant destruction of tissue with
associated systemic signs of sepsis and toxicity. Etanercept is a fully human fusion protein that inhibits tumor
necrosis factor and the inflammatory cascade. It is effective in the treatment of many disorders but concerns
regarding severe life threatening infections have been raised in multiple reports.
Case presentation: We present the case of a 39-year-old Caucasian man, who presented with sudden onset of
severe and progressive neck and left shoulder pain, with a two-year history of seronegative rheumatoid arthritis
treated with azathoprine and etanercept. On examination the left side of his neck and his left shoulder were
oedematous, tender with an erythematous rash and his active range of movement was limited. Magnetic
resonance imaging of his shoulder showed extensive oedema of the subcutaneous and intramuscular fat of the
left lower neck consistent with fasciitis. He was treated medically and made a good recovery.
Conclusion: Our patient, while having a pre-existing increased mortality risk, had a serious infection which
responded well to optimum medical treatment without the need for surgery. As anti tumor necrosis factor agents
are frequently associated with infection, including tuberculous infection, this case highlights the need for a high
index of suspicion for other severe bacterial infections in patients on immunosuppressants.
Introduction
Necrotising fasciitis (NF) is a severe infection charac-
terised by the fulminant destruction of tissue with asso-
ciated systemic signs of sepsis and toxicity. It affects the
skin and fascia and is frequently associated with throm-
bosis of blood vessels and aggressive extension along
fascial planes is associated with a high mortality rate. In
this report, we describe the case of a man with rheuma-
toid arthritis who developed NF of his left shoulder.
There are no previous reports of NF of the shoulder in
association with etanercept treatment published to date.
Case presentation
A 39-year-old Caucasian male presented with the sud-
den onset of severe and progressive neck and left
shoulder pain, radiating down the left arm with
decreased range of movement at the shoulder. He
denied any preceding trauma. His past medical history
was significant for a two-year history of seronegative
rheumatoid arthritis treated with azathoprine and eta-
nercept, the last dose of which had been administered
three weeks prior.
On examination, he was guarding his left neck and
shoulder. He was haemodynamically stable and febrile at
38.3°C. His left shoulder area was oedematous with an
erythematous rash, and was diffusely tender both ante-
riorly and posteriorly. Passive range of movement was
painful and active range of movement was very limited.
Neurological and vascular examinations were normal.
He had no clinical evidence of toxic shock syndrome.
Initial investigations revealed neutrophilia with an ele-
vated CRP and blood cultures were subsequently negative.
Chest radiograph and plain films of the left shoulder and
cervical spine were normal. Differential diagnosis included
septic arthritis, osteomyelitis and localized skin abscess. As
a result, his physician commenced intravenous cefotaxime
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discontinued. Over the following 24 hours he remained
febrile and developed a diffuse macular blanching rash
over the left shoulder with a non-fluctuant boggy swelling
in the left supraclavicular area. Antimicrobial therapy was
changed to intravenous cefotaxime, metronidazole, vanco-
mycin and ciprofloxacin. Serial examination of the
shoulder showed persistent tenderness and progression of
the erythematous macular rash with defined areas across
the left shoulder area, but with no evidence of blistering,
skin eruption or discharge.
As a result of ongoing symptoms, an MRI with intrave-
nous gadolinium contrast of the shoulder was performed
and showed extensive oedema of the subcutaneous and
intramuscular fat of the left lower neck, supraclavicular
region, pectoralis major and teres minor muscles. There
was no evidence of a discreet fluid collection or abnorm-
ality within the muscles or osseus structures. The appear-
ances were felt to be consistent with extensive fasciitis
(Figures 1 and 2). He was clinically improving, as a result
medical and surgical reviewers agreed with antimicrobial
consolidation to intravenous clindamycin, ciprofloxacin,
flucloxacillin and benzylpenicillin with the caveat of close
monitoring and surgical intervention at any sign of dete-
rioration or progression. He clinically improved and
inflammatory indices slowly normalised. He received a
total of 14 days of intravenous antimicrobials followed by
oral equivalents for a further 14 days. Follow up CT of
his shoulder showed resolution of the inflammatory
changes (Figure 3). He was closely followed up as an out-
patient for a number of months after dismissal from the
hospital with no evidence of recurrence.
Discussion
Etanercept is a fully human fusion protein that inhibits
tumor necrosis factor (TNF) and the inflammatory cas-
cade, shown to be safe and effective in the management
of patients with rheumatoid arthritis [1]. It has been
shown to be associated with increased mortality [2] and
with septic shock and disseminated intravascular coagu-
lation [3]. Anti-TNF agents have a substantial risk of
infection with Mycobacterium tuberculosis [4-6].
Figure 1 Coronal oblique fat-suppressed post contrast MRI left
shoulder (TR/TE 5670/75).
Figure 2 Sagittal oblique fat-suppressed post contrast MRI left
shoulder (TR/TE 5670/75). There is extensive subcutaneous
oedema in the soft tissues superficial to the deltoid and rotator cuff
muscles (arrow), consistent with left shoulder fascitis. The underlying
supraspinatous tendon and muscles are normal.
Figure 3 Coronal CT scan post-intravenous contrast following
completion of antibiotic therapy (kVp 120, modulated mA).
There has been almost complete interval resolution of the
subcutaneous oedema, with minimal residual inflammatory fat-
stranding in the supra- and infra-clavicular spaces.
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concerns regarding severe life threatening infections
have been raised in multiple reports including the inci-
dence of opportunistic infection [8].
NF can affect any fascial compartment of the body but
higher rates of mortality are seen in patients with co-
morbidities [9]. NF involvement of the shoulder area is
rare. NF is most commonly associated with Group A
Streptococcus infection, but other organisms have been
implicated. As such, empiric treatment requires the use
of agents targeted against these organisms. NF is a very
serious infection and management is predominantly sur-
gical as excision and debridement of infected tissue is
the mainstay of management. Our patient’s clinical pre-
sentation was atypical and by the time that full diagnosis
was made he had clinically improved with medical man-
agement alone. Our patient did not undergo surgical
management, but would have if there were any evidence
of deterioration or progression.
Most patients who develop necrotising fasciitis have a
predisposing immunocompromising condition or a local
defect [10]. As there was no apparent trauma or inciting
event, we believe that the predisposing factor to the
development of the infection in this case was etanercept.
Conclusion
Our patient, while having a pre-existing increased mor-
tality risk, had a serious infection that responded well to
optimum medical treatment. As anti-TNF agents are
more frequently associated with tuberculous infection,
this case highlights the need for a high index of suspi-
cion for other severe bacterial infections in patients on
immunosuppressants.
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